Literature DB >> 15063013

Functional opioid pathways are necessary for hypocretin-1 (orexin-A)-induced feeding.

Donald C Sweet1, Allen S Levine, Catherine M Kotz.   

Abstract

We investigated the interaction of the orexigenic neuropeptide, hypocretin-1 (Hcrt-1, also known as orexin-A), with endogenous opioids (also orexigenic neuropeptides). Rats were injected with naltrexone (NTX, nonspecific opioid antagonist) i.p., i.c.v., in the lateral hypothalamus (LH), and in the accumbens shell (AcbSh), and naloxone methiodide (nonspecific opioid antagonist unable to cross the blood brain barrier) was injected i.p. Rats were then injected with Hcrt-1 in the LH. Food intake was measured for up to 4h thereafter. Rats were also pretreated with NTX in the LH, with Hcrt-1 injected in the AcbSh. NTX suppressed Hcrt-1-induced feeding only when injected i.p., i.c.v., and in the AcbSh. These studies reveal the necessity for functional central opioidergic pathways involving the AcbSh, but not the LH in Hcrt-1-induced feeding.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15063013     DOI: 10.1016/j.peptides.2003.12.014

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  11 in total

1.  Neurochemical heterogeneity of rats predicted by different measures to be high ethanol consumers.

Authors:  Jessica R Barson; Shawn E Fagan; Guo-Qing Chang; Sarah F Leibowitz
Journal:  Alcohol Clin Exp Res       Date:  2012-06-22       Impact factor: 3.455

2.  Mice lacking δ-opioid receptors resist the development of diet-induced obesity.

Authors:  Traci A Czyzyk; Amparo Romero-Picó; John Pintar; Jaime H McKinzie; Matthias H Tschöp; Michael A Statnick; Ruben Nogueiras
Journal:  FASEB J       Date:  2012-05-16       Impact factor: 5.191

Review 3.  Interacting Neural Processes of Feeding, Hyperactivity, Stress, Reward, and the Utility of the Activity-Based Anorexia Model of Anorexia Nervosa.

Authors:  Rachel A Ross; Yael Mandelblat-Cerf; Anne M J Verstegen
Journal:  Harv Rev Psychiatry       Date:  2016 Nov/Dec       Impact factor: 3.732

4.  Orexin in Rostral Hotspot of Nucleus Accumbens Enhances Sucrose 'Liking' and Intake but Scopolamine in Caudal Shell Shifts 'Liking' Toward 'Disgust' and 'Fear'.

Authors:  Daniel C Castro; Rachel A Terry; Kent C Berridge
Journal:  Neuropsychopharmacology       Date:  2016-01-20       Impact factor: 7.853

5.  Galanin and the orexin 2 receptor as possible regulators of enkephalin in the paraventricular nucleus of the hypothalamus: relation to dietary fat.

Authors:  J R Barson; G-Q Chang; K Poon; I Morganstern; S F Leibowitz
Journal:  Neuroscience       Date:  2011-07-28       Impact factor: 3.590

6.  Orexin A in the rostrolateral hypothalamic area induces feeding by modulating GABAergic transmission.

Authors:  A J Thorpe; D F Doane; D C Sweet; J L Beverly; C M Kotz
Journal:  Brain Res       Date:  2006-11-07       Impact factor: 3.252

Review 7.  Reward processing by the opioid system in the brain.

Authors:  Julie Le Merrer; Jérôme A J Becker; Katia Befort; Brigitte L Kieffer
Journal:  Physiol Rev       Date:  2009-10       Impact factor: 37.312

8.  Hypothalamic injection of non-opioid peptides increases gene expression of the opioid enkephalin in hypothalamic and mesolimbic nuclei: Possible mechanism underlying their behavioral effects.

Authors:  Olga Karatayev; Jessica R Barson; Guo-Qing Chang; Sarah F Leibowitz
Journal:  Peptides       Date:  2009-09-24       Impact factor: 3.750

9.  Hippocampus ghrelin signaling mediates appetite through lateral hypothalamic orexin pathways.

Authors:  Ted M Hsu; Joel D Hahn; Vaibhav R Konanur; Emily E Noble; Andrea N Suarez; Jessica Thai; Emily M Nakamoto; Scott E Kanoski
Journal:  Elife       Date:  2015-12-15       Impact factor: 8.140

10.  Orexin/Hypocretin-1 Receptor Antagonism Selectively Reduces Cue-Induced Feeding in Sated Rats and Recruits Medial Prefrontal Cortex and Thalamus.

Authors:  Sindy Cole; Heather S Mayer; Gorica D Petrovich
Journal:  Sci Rep       Date:  2015-11-05       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.